The TAME trial is the first FDA-approved trial to target aging itself.
Metformin TAME Trial Interim Results
TL;DR
Preliminary data shows metformin may delay onset of age-related diseases by 15-20%.
Credibility Assessment
Verified — 83/100
Study Design
Rigor of the research methodology
19/20
Sample Size
Whether the study was sufficiently powered
20/20
Peer Review
Review status and journal reputation
18/20
Replication
Has this finding been independently reproduced?
8/20
Transparency
Funding disclosure and data availability
18/20
Overall
Sum of all five dimensions
83/100
What this means
Promising results but more studies needed.
0 Comments
Log in to join the discussion.